Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 201

1.

Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy.

Penault-Llorca F, Abrial C, Raoelfils I, Chollet P, Cayre A, Mouret-Reynier MA, Thivat E, Mishellany F, Gimbergues P, Durando X.

Oncologist. 2008 Dec;13(12):1235-45. doi: 10.1634/theoncologist.2008-0073. Epub 2008 Dec 17.

PMID:
19091781
[PubMed - indexed for MEDLINE]
Free Article
2.

Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.

Burcombe R, Wilson GD, Dowsett M, Khan I, Richman PI, Daley F, Detre S, Makris A.

Breast Cancer Res. 2006;8(3):R31. Epub 2006 Jun 21.

PMID:
16790076
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy.

Amat S, Penault-Llorca F, Cure H, Le Bouedëc G, Achard JL, Van Praagh I, Feillel V, Mouret-Reynier MA, Dauplat J, Chollet P.

Int J Oncol. 2002 Apr;20(4):791-6.

PMID:
11894126
[PubMed - indexed for MEDLINE]
4.

Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial: multivariate analysis with Ki-67 index, mitotic count, and microvessel density.

Mandard AM, Denoux Y, Herlin P, Duigou F, van De Vijver MJ, Clahsen PC, van Den Broek L, Sahmoud TM, Henry-Amar M, van De Velde CJ.

Cancer. 2000 Oct 15;89(8):1748-57.

PMID:
11042570
[PubMed - indexed for MEDLINE]
5.

Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancers.

Abrial C, Mouret-Reynier MA, Amat S, Sillet-Bach I, Bougnoux P, Delva R, Cure H, Dauplat J, Penault-Llorca F, Chollet P.

Med Oncol. 2005;22(3):233-40.

PMID:
16110134
[PubMed - indexed for MEDLINE]
6.

The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer.

Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M.

Breast Cancer Res Treat. 2009 Jul;116(1):53-68. doi: 10.1007/s10549-008-0081-7. Epub 2008 Jul 1.

PMID:
18592370
[PubMed - indexed for MEDLINE]
7.

Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Gusterson BA, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Coates AS; International Breast Cancer Study Group.

J Natl Cancer Inst. 2008 Feb 6;100(3):207-12. doi: 10.1093/jnci/djm289. Epub 2008 Jan 29.

PMID:
18230798
[PubMed - indexed for MEDLINE]
Free Article
8.

Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.

Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, Mors R, Haegelé P, Eber M, Ghnassia JP.

Eur J Cancer. 2004 Jan;40(2):205-11.

PMID:
14728934
[PubMed - indexed for MEDLINE]
9.

Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.

Zhou B, Yang DQ, Xie F.

Chin Med J (Engl). 2008 Mar 5;121(5):387-91.

PMID:
18364105
[PubMed - indexed for MEDLINE]
Free Article
10.

[Factors predicting failure of adjuvant hormonotherapy of breast carcinoma. A study in tamoxifen treated patients].

Petráková K, Nenutil R, Grell P, Fabian P, Zichová I, Svoboda M, Palácová M, Vyzula R.

Klin Onkol. 2008;21(5):303-8. Czech.

PMID:
19202962
[PubMed - indexed for MEDLINE]
11.

Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.

Li XR, Liu M, Zhang YJ, Wang JD, Zheng YQ, Li J, Ma B, Song X.

Med Oncol. 2011 Dec;28 Suppl 1:S31-8. doi: 10.1007/s12032-010-9676-z. Epub 2010 Sep 16.

PMID:
20844986
[PubMed - indexed for MEDLINE]
12.

Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile.

Mottolese M, Orlandi G, Sperduti I, Merola R, Buglioni S, Di Benedetto A, Pinnarò P, Perracchio L, Venturo I, Cognetti F, Cianciulli A.

Am J Surg Pathol. 2007 Feb;31(2):247-54.

PMID:
17255770
[PubMed - indexed for MEDLINE]
13.

High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer.

Abrial SC, Penault-Llorca F, Delva R, Bougnoux P, Leduc B, Mouret-Reynier MA, Mery-Mignard D, Bleuse JP, Dauplat J, Curé H, Chollet P.

Breast Cancer Res Treat. 2005 Dec;94(3):255-63. Erratum in: Breast Cancer Res Treat. 2006 Aug;98(3):365. Amat, Catherine [removed]; Abrial, Catherine [corrected to Abrial, Sophie Catherine].

PMID:
16267618
[PubMed - indexed for MEDLINE]
14.

Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer.

Thor AD, Liu S, Moore DH 2nd, Edgerton SM.

J Clin Oncol. 1999 Feb;17(2):470-7.

PMID:
10080587
[PubMed - indexed for MEDLINE]
Free Article
15.

Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy.

Aas T, Geisler S, Eide GE, Haugen DF, Varhaug JE, Bassøe AM, Thorsen T, Berntsen H, Børresen-Dale AL, Akslen LA, Lønning PE.

Eur J Cancer. 2003 Mar;39(4):438-46.

PMID:
12751373
[PubMed - indexed for MEDLINE]
16.

The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.

Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, van de Vijver MJ.

Eur J Surg Oncol. 1999 Aug;25(4):356-63.

PMID:
10419704
[PubMed - indexed for MEDLINE]
17.

Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome.

Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ.

Br J Cancer. 2003 Feb 10;88(3):406-12.

PMID:
12569384
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.

Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF, Filipits M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2008 Mar 15;14(6):1767-74. doi: 10.1158/1078-0432.CCR-07-4122.

PMID:
18347178
[PubMed - indexed for MEDLINE]
Free Article
19.

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.

J Clin Oncol. 2009 Jun 1;27(16):2630-7. doi: 10.1200/JCO.2008.18.8391. Epub 2009 Apr 20.

PMID:
19380449
[PubMed - indexed for MEDLINE]
Free Article
20.

Prognostic significance of mitotic and apoptotic index and the DNA cytometry in head and neck cancer.

Smilek P, Dusek L, Veselý K, Rottenberg J, Kostrica R.

Neoplasma. 2005;52(3):199-207.

PMID:
15875080
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk